DOI: 10.1142/s266131822374393x ISSN: 2661-3182

#184 : Dual Triggers of Ovidrel and Buserelin Improves the Outcome of In Vitro Fertilization in Yasmin Fertility Clinic

Axel Jovito, Fahreza Akbar Siregar, Dafi Yulinda, Louis Regan, Budi Wiweko
  • General Medicine

Introduction: Controlled ovarian stimulation (COS) is a technique used in in vitro fertilization (IVF) to stimulate multiple ovarian follicles at the same time before oocyte retrieval. “Dual triggering” for final oocyte maturation using a gonadotropin-releasing hormone agonist (GnRHa) and human chorionic gonadotropin (hCG) can improve clinical outcomes during in vitro fertilization. We thought that further investigation regarding the efficacy of dual triggers was warranted. In this study, we aim to investigate the outcome of dual triggering in IVF with a combination of a single dose of a GnRH agonist (Buserelin) and rhCG (Ovidrel).

Methods: This retrospective study subjected 22 women who underwent IVF with dual triggers of Ovidrel and Buserelin in Yasmin IVF Center, Dr. Cipto Mangunkusumo General Hospital in Jakarta. Demographic data was gathered from paper-based patient treatment medical records.

Result: Patients who received dual triggers therapy, the average oocyte obtained in the study sample was 11.83 in women under 35 years old (group 1) and 8.27 in women above 35 years old (group 2). The average of embryo day 3 was (7.29 vs 4.40). The average BMI in our study sample was (21.54 vs 24.60), the duration of infertility average was (6.14 vs 8). For the average blastocyst, fertilization rate, cleavage rate, and blastocyst rate consecutively (4.86 vs 3.07, 66.76 vs 66.18, 101.78 vs 87.83, 83.57 vs 73.90).

We found the pregnancy rate was 34,28% (14,28% vs 20,0%) which we assessed based on a positive bHCG result and a P4 value after fresh embryo transfer. No cases of ovarian hyperstimulation syndrome were reported in either group.

Conclusion: Dual triggering of Ovidrel and Buserelin may be a useful maturation treatment to maximize the outcome of mature oocytes in IVF patients. However, further investigation will be needed.

More from our Archive